Francesco Crea
YOU?
Author Swipe
View article: Characterizing resistance in prostate cancer at a single cell level with hormonal treatment and epigenetic inhibitors
Characterizing resistance in prostate cancer at a single cell level with hormonal treatment and epigenetic inhibitors Open
Background Late-stage prostate cancer is treated with hormonal therapy. While initially effective, development of drug resistance is common. Hypoxia, a local-environmental occurrence in tumours, is known to trigger hormone-independence and…
View article: Precision epigenetic therapies in oncology
Precision epigenetic therapies in oncology Open
View article: Deciphering the Transcription Factor Landscape in Prostate Cancer Progression: A Novel Approach to Understand NE Transdifferentiation (Adv. Sci. 20/2025)
Deciphering the Transcription Factor Landscape in Prostate Cancer Progression: A Novel Approach to Understand NE Transdifferentiation (Adv. Sci. 20/2025) Open
Neuroendocrine Transdifferentiation Inspired by the silk‐to‐wing narrative, this frontispiece illustrates prostate cancer lineage transition. Adenocarcinoma appears as a caterpillar, entering a dormant chrysalis for reprogramming before em…
View article: Deciphering the Transcription Factor Landscape in Prostate Cancer Progression: A Novel Approach to Understand NE Transdifferentiation
Deciphering the Transcription Factor Landscape in Prostate Cancer Progression: A Novel Approach to Understand NE Transdifferentiation Open
Prostate cancer (PCa) stands as a leading cause of cancer‐related mortality among men, with treatment‐induced neuroendocrine prostate cancer (NEPC) posing a challenge as an ARPI‐resistant subtype. The role of transcription factors (TFs) in…
View article: EZH2 inhibition enhances the activity of Carboplatin in aggressive-variant prostate cancer cell lines
EZH2 inhibition enhances the activity of Carboplatin in aggressive-variant prostate cancer cell lines Open
EZH2i plus Carboplatin is a promising combination treatment for AVPC.
View article: REST-dependent glioma progression occurs independently of the repression of the long non-coding RNA HAR1A
REST-dependent glioma progression occurs independently of the repression of the long non-coding RNA HAR1A Open
The long non-coding RNA (lncRNA), HAR1A is emerging as a putative tumour suppressor. In non-neoplastic brain cells, REST suppresses HAR1A expression. In gliomas REST acts as an oncogene and is a potential therapeutic target. It is therefor…
View article: Both Maternal High-Fat and Post-Weaning High-Carbohydrate Diets Increase Rates of Spontaneous Hepatocellular Carcinoma in Aged-Mouse Offspring
Both Maternal High-Fat and Post-Weaning High-Carbohydrate Diets Increase Rates of Spontaneous Hepatocellular Carcinoma in Aged-Mouse Offspring Open
Both maternal obesity and postnatal consumption of obesogenic diets contribute to the development of metabolic dysfunction-associated steatotic liver disease (MASLD) and hepatocellular carcinoma (HCC). However, there is no consensus as to …
View article: Deciphering the Transcription Factor Landscape in Neuroendocrine Prostate Cancer Progression: A Novel Approach to Understand NE Transdifferentiation
Deciphering the Transcription Factor Landscape in Neuroendocrine Prostate Cancer Progression: A Novel Approach to Understand NE Transdifferentiation Open
Background and Objective Prostate cancer (PCa) is a leading cause of cancer mortality in men, with neuroendocrine prostate cancer (NEPC) representing a particularly resistant subtype. The role of transcription factors (TFs) in the progress…
View article: Comprehensive analysis of differentially expressed miRNAs in hepatocellular carcinoma: Prognostic, predictive significance and pathway insights
Comprehensive analysis of differentially expressed miRNAs in hepatocellular carcinoma: Prognostic, predictive significance and pathway insights Open
Robust prognostic and predictive factors for hepatocellular carcinoma, a leading cause of cancer-related deaths worldwide, have not yet been identified. Previous studies have identified potential HCC determinants such as genetic mutations,…
View article: Comprehensive analysis of differentially expressed miRNAs in Hepatocellular carcinoma: prognostic significance and pathway insights
Comprehensive analysis of differentially expressed miRNAs in Hepatocellular carcinoma: prognostic significance and pathway insights Open
Robust prognostic and predictive factors for hepatocellular carcinoma, a leading cause of cancer-related deaths worldwide, have not yet been identified. Previous studies have identified potential HCC determinants such as genetic mutations,…
View article: P-54 Circulating immune cells as a tool to predict benefit from atezolizumab/bevacizumab in advanced hepatocellular carcinoma (aHCC)
P-54 Circulating immune cells as a tool to predict benefit from atezolizumab/bevacizumab in advanced hepatocellular carcinoma (aHCC) Open
View article: Data from Molecular Mechanisms Involved in the Synergistic Interaction of the EZH2 Inhibitor 3-Deazaneplanocin A with Gemcitabine in Pancreatic Cancer Cells
Data from Molecular Mechanisms Involved in the Synergistic Interaction of the EZH2 Inhibitor 3-Deazaneplanocin A with Gemcitabine in Pancreatic Cancer Cells Open
Pancreatic ductal adenocarcinoma (PDAC) is characterized by overexpression of enhancer of Zeste homolog-2 (EZH2), which plays a pivotal role in cancer stem cell (CSC) self-renewal through methylation of histone H3 lysine-27 (H3K27me3). Aga…
View article: Data from Molecular Mechanisms Involved in the Synergistic Interaction of the EZH2 Inhibitor 3-Deazaneplanocin A with Gemcitabine in Pancreatic Cancer Cells
Data from Molecular Mechanisms Involved in the Synergistic Interaction of the EZH2 Inhibitor 3-Deazaneplanocin A with Gemcitabine in Pancreatic Cancer Cells Open
Pancreatic ductal adenocarcinoma (PDAC) is characterized by overexpression of enhancer of Zeste homolog-2 (EZH2), which plays a pivotal role in cancer stem cell (CSC) self-renewal through methylation of histone H3 lysine-27 (H3K27me3). Aga…
View article: Supplementary Figure 2 from Molecular Mechanisms Involved in the Synergistic Interaction of the EZH2 Inhibitor 3-Deazaneplanocin A with Gemcitabine in Pancreatic Cancer Cells
Supplementary Figure 2 from Molecular Mechanisms Involved in the Synergistic Interaction of the EZH2 Inhibitor 3-Deazaneplanocin A with Gemcitabine in Pancreatic Cancer Cells Open
PDF file, 117KB, Protein expression of E-cadherin, as detected by immunocytochemistry.
View article: Supplementary Figure 1 from Molecular Mechanisms Involved in the Synergistic Interaction of the EZH2 Inhibitor 3-Deazaneplanocin A with Gemcitabine in Pancreatic Cancer Cells
Supplementary Figure 1 from Molecular Mechanisms Involved in the Synergistic Interaction of the EZH2 Inhibitor 3-Deazaneplanocin A with Gemcitabine in Pancreatic Cancer Cells Open
PDF file, 694KB, Effects of DZNeP/gemcitabine combination on PDAC cells migration.
View article: Supplementary Figure 1 from Molecular Mechanisms Involved in the Synergistic Interaction of the EZH2 Inhibitor 3-Deazaneplanocin A with Gemcitabine in Pancreatic Cancer Cells
Supplementary Figure 1 from Molecular Mechanisms Involved in the Synergistic Interaction of the EZH2 Inhibitor 3-Deazaneplanocin A with Gemcitabine in Pancreatic Cancer Cells Open
PDF file, 694KB, Effects of DZNeP/gemcitabine combination on PDAC cells migration.
View article: Supplementary Figure 2 from Molecular Mechanisms Involved in the Synergistic Interaction of the EZH2 Inhibitor 3-Deazaneplanocin A with Gemcitabine in Pancreatic Cancer Cells
Supplementary Figure 2 from Molecular Mechanisms Involved in the Synergistic Interaction of the EZH2 Inhibitor 3-Deazaneplanocin A with Gemcitabine in Pancreatic Cancer Cells Open
PDF file, 117KB, Protein expression of E-cadherin, as detected by immunocytochemistry.
View article: Supplementary Figure Legend from Molecular Mechanisms Involved in the Synergistic Interaction of the EZH2 Inhibitor 3-Deazaneplanocin A with Gemcitabine in Pancreatic Cancer Cells
Supplementary Figure Legend from Molecular Mechanisms Involved in the Synergistic Interaction of the EZH2 Inhibitor 3-Deazaneplanocin A with Gemcitabine in Pancreatic Cancer Cells Open
PDF file, 69KB.
View article: Supplementary Figure Legend from Molecular Mechanisms Involved in the Synergistic Interaction of the EZH2 Inhibitor 3-Deazaneplanocin A with Gemcitabine in Pancreatic Cancer Cells
Supplementary Figure Legend from Molecular Mechanisms Involved in the Synergistic Interaction of the EZH2 Inhibitor 3-Deazaneplanocin A with Gemcitabine in Pancreatic Cancer Cells Open
PDF file, 69KB.
View article: Data from Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines
Data from Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines Open
Irinotecan is a topoisomerase-I (Top-I) inhibitor used for the treatment of colorectal cancer. DNA demethylating agents, including 5-azacytidine (5-aza), display synergistic antitumor activity with several chemotherapy drugs. 5-Aza may enh…
View article: Supplementary Fig. S1 from Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines
Supplementary Fig. S1 from Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines Open
Supplementary Fig. S1 from Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines
View article: Supplementary Information from Heterochromatin Protein 1α Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer
Supplementary Information from Heterochromatin Protein 1α Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer Open
Supplementary materials and methods used in this study. Supplementary table with primer sequences. Figure S1, Histological feature of PDX models and heatmaps of PDX and clinical cohorts. Figure S2, IHC staining of HP1α in PDX models, and e…
View article: Data from Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines
Data from Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines Open
Irinotecan is a topoisomerase-I (Top-I) inhibitor used for the treatment of colorectal cancer. DNA demethylating agents, including 5-azacytidine (5-aza), display synergistic antitumor activity with several chemotherapy drugs. 5-Aza may enh…
View article: Data from Heterochromatin Protein 1α Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer
Data from Heterochromatin Protein 1α Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer Open
Neuroendocrine prostate cancer (NEPC) is a lethal subtype of prostate cancer arising mostly from adenocarcinoma via neuroendocrine transdifferentiation following androgen deprivation therapy. Mechanisms contributing to both NEPC developmen…
View article: Supplementary Information from Heterochromatin Protein 1α Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer
Supplementary Information from Heterochromatin Protein 1α Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer Open
Supplementary materials and methods used in this study. Supplementary table with primer sequences. Figure S1, Histological feature of PDX models and heatmaps of PDX and clinical cohorts. Figure S2, IHC staining of HP1α in PDX models, and e…
View article: Data from Heterochromatin Protein 1α Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer
Data from Heterochromatin Protein 1α Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer Open
Neuroendocrine prostate cancer (NEPC) is a lethal subtype of prostate cancer arising mostly from adenocarcinoma via neuroendocrine transdifferentiation following androgen deprivation therapy. Mechanisms contributing to both NEPC developmen…
View article: Supplementary Fig. S1 from Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines
Supplementary Fig. S1 from Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines Open
Supplementary Fig. S1 from Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines
View article: Calcium signalling pathways in prostate cancer initiation and progression
Calcium signalling pathways in prostate cancer initiation and progression Open
View article: Find the culprit
Find the culprit Open
In Forensic Geology, Environmental Forensics is devoted to ascertaining contaminants in the soil/subsoil, surface waters, and groundwaters. In such cases, forensic geologists usually accomplish activities concerning geological, hydrogeolog…
View article: Marine Natural Products with Activities against Prostate Cancer: Recent Discoveries
Marine Natural Products with Activities against Prostate Cancer: Recent Discoveries Open
Prostate cancer is the most common cancer in men, with over 52,000 new cases diagnosed every year. Diagnostics and early treatment are potentially hindered by variations in screening protocols, still largely reliant on serum levels of acid…